Reviews/Alzheimers Disease Treatment/Multidomain lifestyle slows decline
Prevention · AD-PREV-02 · v2
Several separate randomised trials tested programmes that combine diet, exercise, mental activity and management of blood-pressure and other risks in older adults who are at higher-than-average risk of memory problems. In four of these trials, the people who got the programme did better on memory and thinking tests than those who did not [1][21][18][20]. The size of the gain was generally small, and the trials measured performance on thinking tests rather than whether people actually went on to develop dementia. One large United States trial compared two versions of the programme against each other, with no untreated group, and found no difference between them [10]. The panel judged the benefit real but modest, which is why it sits below the top tier.
Four independent randomised trials in at-risk older adults report a statistically significant cognitive advantage for a multidomain lifestyle programme: FINGER [1], the online Maintain Your Brain trial [21], SUPERBRAIN-MEET [18] and PROMED-EX [20]. Within FINGER, people who engaged more with the programme and changed more lifestyle behaviours improved more [22], and higher engagement tracked with better cognitive trajectories out to 11 years [25]. Effect sizes are modest: FINGER's between-group difference was 0·022 NTB points per year [1], and PROMED-EX reported NTB z-score differences of 0·2 to 0·3 [20]. Every trial used cognitive test batteries as the outcome, not incident dementia. Observational and secondary work [9][28][31] and the FINGER subgroup analyses [23][24][26] are consistent but do not themselves establish the effect. The contested point: The division is over how firmly and how absolutely the benefit holds. The four positive trials measure test-performance surrogates rather than dementia incidence [1][18][20][21], and the large POINTER trial [10] found no difference between its two active arms and had no untreated control, so it cannot confirm an absolute effect even though it does not refute one.
All 39 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alzheimers Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The largest US trial, POINTER [10], reported no intervention-group differences in cognition and compared two active arms (structured vs self-guided) with no untreated control, so it cannot establish an absolute effect and tempers the positive signal.
Outcomes are cognitive test batteries (NTB/RBANS z-scores), a surrogate; no included trial demonstrates reduced dementia incidence, so 'slows cognitive decline' is supported only at the test-performance level.
Where it remains uncertain. Effects are modest and measured as cognitive-test surrogates, and the large POINTER trial [10] found no between-arm difference with no untreated control.
Aleatory
Benefit varies by engagement, baseline risk and characteristics [22][24][26], so any single at-risk person's outcome is uncertain.
The load-bearing papers from a corpus of 39, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Landmark double-blind RCT: statistically significant cognitive benefit in at-risk elderly.
“Between-group difference in the change of NTB total score per year was 0·022 (95% CI 0·002-0·042, p=0·030).”
Panel auditInternal validity: high · scope of inference: General-population adults 60-77 with CAIDE risk score ≥6 and average-or-below cognition.Key limitations: small absolute effect size · surrogate cognitive outcome not clinical dementia · more adverse events in intervention arm
Independent Korean RCT showing cognitive benefit in at-risk/MCI older adults.
“MLI significantly improved RBANS total index scores compared with control at 24 weeks (between-group difference, 4.17 points; 95% CI 1.92-6.43).”
Panel auditInternal validity: high · scope of inference: South Korean adults 60-85 with MCI over 24 weeks.Key limitations: short 24-week follow-up · MCI not primary-prevention population · subgroup analyses underpowered
Independent RCT: multidomain diet/exercise improved cognition in at-risk older adults.
“Cognitive function also improved, with NTB z-score differences of 0.3 (95% CI: 0.1, 0.5; P = 0.01) in PROMED and 0.2 (95% CI: 0.0, 0.4; P = 0.02) in PROMED-EX compared with CON.”
Panel auditInternal validity: medium · scope of inference: Community-dwelling older adults at risk of undernutrition and cognitive decline.Key limitations: only two domains (diet, exercise) · cognition secondary, short 6-month window · small sample
Both arms were active multidomain interventions, so a null between them cannot say whether intervention slows decline versus no intervention.
Panel auditInternal validity: high · scope of inference: Brain-biomarker and cognitive response to intervention intensity in at-risk adults 60-79.Key limitations: no untreated control · imaging ancillary subset · subgroup interactions exploratory
4 of 39 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independent RCT support establishes a real benefit, but modest effect sizes, surrogate outcomes and POINTER's ambiguity keep confidence at Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Dementia-incidence endpoint. The claim is supported only at the test-performance level; no corpus trial shows fewer dementia diagnoses [1][18][20][21]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-horizon multidomain RCT powered for incident dementia or clinical progression as the primary outcome.
Open question: Does a multidomain lifestyle intervention reduce incident dementia, not just slow cognitive-test decline? Why it is still open: Every included trial uses cognitive-test batteries as the outcome [1][18][20][21]; none reports dementia incidence.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19